Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 06-10 15:00:00

22.11

+0.28

+1.28%

High22.15	Low21.70	Vol15.38M
Open21.77	D1 Closing21.83	Amplitude2.06%
Mkt Cap59.03B	Tradable Cap46.83B	Total Shares2.67B
T/O338.00M	T/O Rate0.73%	Tradable Shares2.12B
P/B1.2	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":22.11,"timestamp":1781074800000,"preClose":21.83,"halted":0,"volume":15377234,"delay":0,"changeRate":0.0128,"floatShares":2118000000,"shares":2670000000,"eps":1.3019,"marketStatus":"Closed","change":0.28,"latestTime":"06-10 15:00:00","open":21.77,"high":22.15,"low":21.7,"amount":338000000,"amplitude":0.0206,"askPrice":22.12,"askSize":80,"bidPrice":22.11,"bidSize":319,"shortable":0,"etf":0,"ttmEps":1.3019,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781141400000},"marketStatusCode":5,"adr":0,"adjPreClose":21.83,"symbolType":"stock","openAndCloseTimeList":[[1781055000000,1781062200000],[1781067600000,1781074800000]],"highLimit":24.01,"lowLimit":19.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.2,"roa":"--","peRate":16.982871,"roe":"1.78%","epsLYR":1.27,"committee":-0.435897,"marketValue":59043000000,"turnoverRate":0.0073,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":16.31,"timestamp":1781078947004,"preClose":16.15,"halted":0,"volume":2594186,"delay":0,"premium":"-36.19"},"floatMarketCap":46840000000},"requestUrl":"/m/hq/s/600196/tweets","defaultTab":"tweets","newsList":[{"id":"2639626717","title":"BRIEF-Fosun Pharma Says Henlius Biotech's Pertuzumab Injection Approved By China Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2639626717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639626717?lang=en_us&edition=fundamental","pubTime":"2026-05-29 18:03","pubTimestamp":1780049025,"startTime":"0","endTime":"0","summary":"BRIEF-Fosun Pharma Says Henlius Biotech's Pertuzumab Injection Approved By China RegulatorMay 29  - Fosun Pharma 600196.SS:SAYS UNIT HENLIUS BIOTECH'S PERTUZUMAB INJECTION APPLICATION APPROVED BY CHINA REGULATORSource textFurther company coverage: 600196.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4N4260WL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","BK0060","600196","BK0028","HK0000165453.HKD","BK0188","02696","BK0012","BK0196","HK0000306701.USD","BK0187","HK0000320223.HKD","HK0000306685.HKD","BK1161","BK0096","BK0175","BK0183","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109704816","title":"Subsidiary of FOSUN PHARMA Gains Approval for Pertuzumab Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1109704816","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109704816?lang=en_us&edition=fundamental","pubTime":"2026-05-29 16:44","pubTimestamp":1780044278,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries (collectively referred to as \"Henlius\") have received approval from...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","600196","02196","BK0096","BK0012","BK1593","BK0060","BK0028","BK0183","BK0187","BK0188","BK1515","BK0239","BK0196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669224","title":"Shanghai Fosun Pharmaceutical Says Genrix Granted Yaoyou Exclusive Greater China Rights to Develop, Commercialise and Manufacture an Antibody-Based Drug Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669224","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638669224?lang=en_us&edition=fundamental","pubTime":"2026-05-28 17:32","pubTimestamp":1779960769,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL4N4250SN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0187","BK0175","688443","BK0188","BK0239","BK0096","BK0196","BK0012","BK0060","600196","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669226","title":"Shanghai Fosun Pharmaceutical  Says Unit Yaoyou Pharmaceutical Signed Licensing Agreement With Genrix Biopharmaceutical for up to 600 Mln Yuan in Upfront, Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638669226?lang=en_us&edition=fundamental","pubTime":"2026-05-28 17:32","pubTimestamp":1779960768,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL4N4250SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0060","BK0239","BK0183","BK0012","BK0196","688443","600196","BK0175","BK0028","BK0187","BK0188","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139019021","title":"FOSUN PHARMA Invests Over 400 Million Yuan in Nucleic Acid Drug Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=1139019021","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139019021?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:06","pubTimestamp":1779883577,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA recently announced that its controlling subsidiary, Fosun Pharmaceutical Industry, plans to invest approximately 414 million yuan to acquire a 20.87% equity stake in Xingyao Kunze. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0175","BK0183","02196","BK0188","BK0012","BK0096","BK1191","600196","BK1515","BK0028","BK1593","BK0196","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638088975","title":"Sinopharm Group  Stock Falls 1.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2638088975","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638088975?lang=en_us&edition=fundamental","pubTime":"2026-05-27 16:33","pubTimestamp":1779870780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slipped 1.7% to 17.13 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.1% to 25328.23.This was the stock's second consecutive day of losses.Sinopharm Group Co. Ltd. closed 23% short of its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 1.6%.Trading volume totaled 5.6 million shares, compared to the 50-day average of 5.6 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","SHTDY","BK1515","01099","LU1115378108.SGD","BK0183","BK0196","BK1197","BK0096","BK1593","BK0188","BK1191","LU0640798160.USD","BK0012","BK0175","BK0028","BK0239","02196","BK0060","BK1500","BK4175","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574536","title":"Fosun Pharmaceutical to Invest 414 Million Yuan in Xingyao Kunze's Series B Funding Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574536","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638574536?lang=en_us&edition=fundamental","pubTime":"2026-05-27 14:52","pubTimestamp":1779864731,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical , through subsidiary Fosun Pharma Industry, plans to invest 414.4 million yuan to participate in the Series B financing of Xingyao Kunze, according to a Wednesday filing on the Shanghai bourse.Xingyao Kunze develops drugs for liver diseases. Its pipeline products are HT-101 and HT-102, and the combination of these drugs.After the completion of the funding round, Fosun Pharma Industry is expected to own 20.9% of Xingyao Kunze.The pharmaceutical company's Hong Kong shares fell by less than 2% during the afternoon trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0060","BK0196","BK0012","BK1515","02196","BK0188","BK1593","BK0187","BK0183","BK0096","600196","BK0028","BK1191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638971265","title":"BRIEF-Shanghai Fosun Pharma' Unit To Invest In Hepa Thera Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638971265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638971265?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:07","pubTimestamp":1779786427,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma' Unit To Invest In Hepa Thera FinancingMay 26  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS UNIT PLANS TO INVEST 414.4 MILLION YUAN  IN HEPA THERA ROUND B FINANCINGSource textFurther company coverage: 600196.SS  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL4N4230HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","600196","BK0188","BK0096","BK0012","BK0196","BK0239","BK0187","BK0183","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638259714","title":"Shanghai Fosun Pharma  Says Unit Plans to Invest 414.4 Mln Yuan in Hepa Thera Round B Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638259714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638259714?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:07","pubTimestamp":1779786427,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL4N4230HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0175","BK0196","BK0187","BK0096","600196","BK0183","BK0188","BK0239","BK0028","BK0012","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333044","title":"Fosun Pharma Gets Registration Nod for Infection Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333044","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333044?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:06","pubTimestamp":1779365173,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  unit Yaopharma obtained drug registration approval for the Levofloxacin Injection from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The approved indication is for various mild, moderate, and severe infections caused by susceptible bacteria, including pneumonia, acute bacterial sinusitis, skin infections urinary tract infections, and more.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","BK0012","BK0187","BK0060","BK0183","BK0188","BK0239","BK1515","600196","BK0175","02196","BK0028","BK0096","BK1191","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145508249","title":"FOSUN PHARMA Subsidiary Gains Approval for Levofloxacin Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1145508249","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145508249?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:54","pubTimestamp":1779357260,"startTime":"0","endTime":"0","summary":"Recently, the holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Chongqing Youcare Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK0096","BK0028","600196","BK0012","BK1515","BK0196","BK0175","BK0188","BK0239","BK1191","BK0060","BK0183","02196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637381381","title":"Shanghai Fosun Pharma -  Drug Registration Application for Levofloxacin Injection Approved by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2637381381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637381381?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:44","pubTimestamp":1779356690,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y07L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0175","BK0196","BK0187","BK0096","BK1191","600196","BK0183","BK1515","BK1593","BK0188","BK0239","BK0028","BK0012","02196","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181687396","title":"FOSUN PHARMA Subsidiary's HLX3902 Injection Approved for Clinical Trials in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=1181687396","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181687396?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:04","pubTimestamp":1779354280,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries, has received approval for the Phase I clinical trial protocol of its self-developed...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","600196","BK0096","BK0175","BK1593","BK0188","BK0183","BK0060","BK0196","BK0187","BK1515","BK0012","BK0028","02196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637385819","title":"Sinopharm Group  Stock Sheds 1.2% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2637385819","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637385819?lang=en_us&edition=fundamental","pubTime":"2026-05-21 16:33","pubTimestamp":1779352380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slid 1.2% to 17.52 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.0% to 25386.52.The stock's fall snapped a two-day winning streak.Sinopharm Group Co. Ltd. closed 22% short of its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 1.0%.Trading volume totaled 7.2 million shares, compared to the 50-day average of 5.7 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK1593","BK0096","BK0012","BK0196","01099","BK1500","BK0239","02196","600196","BK4175","BK1515","BK0175","LU1115378108.SGD","BK0028","BK0183","SHTDY","BK0060","BK0187","BK0188","BK1191","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636253630","title":"Sinopharm Group  Stock Falls 2.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2636253630","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636253630?lang=en_us&edition=fundamental","pubTime":"2026-05-18 16:33","pubTimestamp":1779093180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slipped 2.1% to 17.51 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.1% to 25675.18.This was the stock's fourth consecutive day of losses.Sinopharm Group Co. Ltd. closed 22% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 1.8%.Trading volume totaled 5.7 million shares, compared to the 50-day average of 5.7 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","LU1115378108.SGD","02196","SHTDY","BK0012","BK0188","BK1191","BK0183","01099","BK0239","BK0028","LU0640798160.USD","BK0187","BK0175","600196","BK4175","BK1515","BK0196","BK0096","BK1593","BK1197","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123897620","title":"FOSUN PHARMA's Strategic Move: $60 Million Secures Potential Over $2.5 Billion for AR1001","url":"https://stock-news.laohu8.com/highlight/detail?id=1123897620","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123897620?lang=en_us&edition=fundamental","pubTime":"2026-05-14 17:49","pubTimestamp":1778752148,"startTime":"0","endTime":"0","summary":"On May 13th, an agreement between FOSUN PHARMA (600196; 02196) and South Korea's AriBio sent significant ripples through China's pharmaceutical investment community. This is not merely a transaction...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0060","BK0183","BK0175","BK0187","BK0188","BK0096","BK1191","600196","BK1593","BK0012","BK0196","BK1515","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635645367","title":"Fosun Pharma Secures $60 Million Option for Alzheimer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2635645367","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635645367?lang=en_us&edition=fundamental","pubTime":"2026-05-14 12:37","pubTimestamp":1778733478,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0239","BK1191","BK1593","600196","BK0012","02196","BK0060","BK0196","BK1515","BK0188","BK0187","BK0028","BK0175","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635752291","title":"Fosun Pharma and Aribio Sign Exclusive Global Option Agreement for Ar1001 for the Treatment of Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2635752291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635752291?lang=en_us&edition=fundamental","pubTime":"2026-05-14 08:00","pubTimestamp":1778716800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAB9QT14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0175","BK0188","BK0060","BK0028","BK0183","BK0187","600196","BK0239","BK0096","BK0012","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148828379","title":"China's AI Power Consumption Set to Soar, Spotlight on Computing-Power Synergy","url":"https://stock-news.laohu8.com/highlight/detail?id=1148828379","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148828379?lang=en_us&edition=fundamental","pubTime":"2026-05-14 07:33","pubTimestamp":1778715233,"startTime":"0","endTime":"0","summary":"【Top Story】China's AI Power Consumption Set to Soar, Spotlight on Computing-Power Synergy With the official implementation of the \"Action Plan for Promoting Mutual Empowerment of Artificial...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03813","IE00BGV7N243.SGD","LU0588545730.USD","LU1688375341.USD","TCEHY","IE0008368411.USD","LU0293314216.USD","LU1226288097.SGD","BK1526","SG9999004220.SGD","IE0009570106.USD","LU0456846285.SGD","LU0531970944.HKD","IE00B3M56506.USD","IE00B8L5B284.USD","LU0700851271.USD","HK0001040168.HKD","IE0032834883.USD","LU1044876610.USD","LU0127658192.USD","LU1235295612.USD","LU2133065610.SGD","SG9999001069.SGD","LU0348784397.USD","LU0708995153.HKD","LU0181495838.USD","LU1196710195.USD","LU0214875030.USD","LU1568876335.HKD","LU0140636845.USD","LU0880133367.SGD","SG9999014674.SGD","GB00BDT5M118.USD","LU1105468828.SGD","LU0348783233.USD","LU0501845795.SGD","LU2097828714.EUR","LU1880383366.USD","LU0052750758.USD","LU0633140727.USD","LU2045819591.USD","LU0043850808.USD","LU2237443382.USD","LU1226287875.USD","LU0210526637.USD","TCHmain","BK1517","LU1102505762.USD","SG9999007991.SGD","LU0516422952.EUR","LU0456827905.SGD","LU0589944569.HKD","LU1152091754.HKD","LU1718418525.SGD","LU2294711473.HKD","LU0634319403.HKD","LU2476274308.USD","LU1044875133.USD","LU0259732245.USD","LU0502904849.HKD","LU1051768304.USD","HK0000151867.HKD","LU0051755006.USD","LU0417516738.SGD","LU0211331839.USD","LU0348783662.USD","LU0499858602.USD","LU0737861699.HKD","LU1961090484.USD","LU0786609619.USD","LU0823413587.USD","LU1974910355.USD","LU2778985437.USD","LU2498475776.HKD","LU0878005551.USD","LU1282649810.SGD","LU2226246903.HKD","LU0499858438.USD","LU0633140560.USD","LU0791590937.USD","LU1188198961.HKD","SG9999013353.USD","LU0516423174.USD","LU1226288170.HKD","LU0856984785.SGD","SG9999002463.SGD","LU0128522157.USD","TSLA","LU0431992006.USD","LU1366334651.USD","LU0235996351.USD","LU0871576103.HKD","LU0163747925.USD","LU0868486357.SGD","LU2257852520.SGD","BK1609","LU0396098781.USD","LU1770034418.SGD","LU1807302812.USD","LU1282649141.HKD","LU0577902298.EUR","LU0577902611.USD","IE00BQXX3F31.USD","HTCD.SI","LU0823039010.USD","LU0315178854.USD","LU1993786604.SGD","LU0348788117.USD","LU0608807433.USD","LU0516423091.SGD","IE00B29SXG58.USD","LU0543330566.HKD","LU0543330483.HKD","LU0594300419.USD","LU2051468812.USD","SG9999006597.SGD","LU0882747503.HKD","LU1642822792.SGD","LU0561508036.HKD","LU2023250504.SGD","SG9999003461.SGD","HK0000352382.USD","LU1880383440.USD","LU0414403682.SGD","LU0067412154.USD","LU0819121731.USD","LU1023057109.AUD","LU1282651048.USD","LU0455707207.USD","LU1282649067.USD","LU0797268264.HKD","LU1733274473.HKD","LU1883866441.USD","IE00B031HY20.USD","HK0001040143.USD","LU2087589342.USD","IE00B067MR52.USD","IE00BF5LJ272.USD","SG9999001903.USD","SGXZ31699556.SGD","LU1224444064.USD","SGXZ99366536.SGD","LU0264606111.USD","LU2097828474.EUR","LU0348735423.USD","LU0117844026.USD","LU0593848301.USD","LU1008478684.HKD","LU0531971595.HKD","IE00BZ08YT58.USD","LU0287142896.SGD","IE00B0169N27.USD","LU0572940350.SGD","IE00B5MMRT66.SGD","LU1734074674.USD","LU0791591158.USD","LU2237443622.USD","BK1615","LU1655091459.SGD","LU0261950983.USD","SG9999015978.USD","LU1064131003.USD","SG9999001051.SGD","IE00BQXX3D17.EUR","LU0196878994.USD","IE00B8HQ1Z84.USD","LU1051769294.HKD","LU3063872942.SGD","LU0823426480.USD","LU1868838027.USD","LU0577902538.SGD","LU1868837722.USD","LU0588545490.SGD","SG9999014914.USD","LU0985320562.USD","LU1226287792.SGD","LU0831103253.SGD","LU0611395673.USD","LU2462611646.USD","09988","LU0029875118.USD","HK0000320264.USD","LU0192582467.USD","LU0117841782.USD","HK0000306685.HKD","LU1917777945.USD","LU2317271919.USD","LU0540923850.HKD","LU0605514214.HKD","LU1064130708.USD","LU1813983027.USD","LU0456842615.SGD","IE00B97KM107.HKD","LU0329678337.USD","LU2008162690.USD","LU1226287529.USD","LU1810669033.SGD","LU2097828631.EUR","LU0175139822.USD","IE0008369823.USD","LU0823040885.USD","002352","LU0329678170.USD","BK1610","HK0000306701.USD","LU0164880469.USD","LU0320764243.SGD","LU0054450605.USD","LU0169518387.USD","BK1586","LU0348816934.USD","IE0003851619.USD","LU2237443465.HKD","LU2152927971.USD","META","LU0441854154.USD","LU2293587155.HKD","LU0577902454.USD","LU0054237671.USD","LU0061477393.USD","LU1439103000.SGD","LU0345769631.USD","LU0823397285.USD","LU0886674414.USD","SG9999000418.SGD","BK1591","LU1328277881.USD","LU1831875114.USD","LU2476274720.SGD","SG9999000327.SGD","BABA","LU2125910500.SGD","LU2177674079.SGD","LU0307460666.USD","LU0345776255.USD","LU1102505929.USD","LU1048484197.HKD","LU0509642566.USD","SG9999000459.SGD","BK1516","LU0650527681.SGD","LU0047713382.USD","LU0359201885.HKD","IE00BQXX3C00.GBP","LU1242518931.SGD","LU0070217475.USD","LU1733274390.USD","LU2399975544.HKD","LU2362541513.USD","LU1044874839.SGD","LU0029874905.USD","SG9999006514.SGD","LU0370786039.SGD","IE0003795394.USD","LU0865486749.SGD","LU0821914370.USD","LU0039217434.USD","LU1323998911.USD","LU0979878070.USD","LU0289960550.SGD","LU0862451837.USD","BK1608","SG9999001226.SGD","SG9999014898.SGD","LU0210527791.USD","LU0328353924.USD","LU0417516902.SGD","BK1502","SG9999002562.SGD","BK1095","IE00B0JY6N72.USD","SG9999001093.SGD","LU0096374516.USD","LU1152091168.USD","LU1725190679.HKD","03700","00659","SG9999001689.USD","LU0823413660.USD","LU1769817179.HKD","LU0072462343.USD","IE00B031J352.USD","NWSGY","01070","LU0128522744.USD","LU0327786744.USD","LU1196710351.USD","LU0819123356.HKD","HK0000914686.HKD","LU0918141887.USD","LU1242518857.USD","LU0315179316.USD","SG9999018865.SGD","SG9999015945.SGD","SGXZ90724238.SGD","BK4585","LU1515016050.SGD","LU1675838814.USD","SG9999017495.SGD","LU0143863784.USD","LU0577902371.SGD","LU1629966141.USD","LU2125910849.SGD","LU0608807946.USD","LU0228659784.USD","LU0229945570.USD","LU0738912210.USD","LU0469268626.HKD","LU0084288322.USD","LU0106252389.USD","LU0541501648.USD","LU1785774172.SGD","BK1557","LU0210533765.USD","LU1981816686.USD","LU0348723411.USD","LU0320764599.SGD","LU0048388663.USD","LU0203347892.USD","LU0918141705.HKD","LU1224709979.USD","IE00B0169L03.USD","LU0594300179.USD","LU0348814723.USD","02196","IE0034224299.USD","LU0675040207.SGD","LU1504937902.USD","LU0203345920.USD","LU0873338254.USD","GOOGL","LU0048580855.USD","LU0823397103.USD","LU0572939691.SGD","LU0348825331.USD","IE0032431581.USD","IE00BPRC5H50.USD","LU0648948544.HKD","LU0972618739.USD","LU0823041008.USD","LU1226288253.USD","LU0607220059.USD","LU0862451753.SGD","LU1316542783.SGD","LU0708995583.HKD","LU1719994722.HKD","LU0488056044.USD","LU0107464264.USD","LU1328615791.USD","SGXZ81514606.USD","LU0878004406.USD","SG9999002828.SGD","SG9999014880.SGD","LU1691799644.USD","BK4588","LU2148510915.USD","LU0828238088.HKD","LU2251237488.HKD","IE0001KFT4U8.USD","LU0345769128.USD","LU0048597586.USD","LU0348827113.USD","LU0106959298.USD","LU1720050803.USD","LU1303224171.USD","LU0106259558.USD","LU0244354667.USD","NVDA","LU1366334578.USD","LU0541502299.USD","LU0588545904.SGD","LU0823426308.USD","SGXZ51526630.SGD","LU0011963245.USD","LU1770036033.HKD","LU2237443978.SGD","LU1769817096.USD","LU0588546209.SGD","LU1481107354.HKD","LU1046422090.SGD","LU2362540622.SGD","LU0417516571.SGD","LU0320764755.SGD","SG9999015986.USD","SG9999014906.USD","LU1808992512.USD","LU0516422366.SGD","LU0516422440.USD","00700","LU1048588211.SGD","LU2242644610.SGD","LU0348805143.USD","LU0165289439.USD","LU1868837565.USD","LU1282648689.USD","LU0828237510.HKD","LU0672654166.SGD","LU1956131251.USD","HK0000914660.USD","IE00B543WZ88.USD","LU1048596156.SGD","LU0149721374.USD","LU0164872284.USD","LU0326950275.SGD","LU0359202008.SGD","LU0449509016.USD","HK0000320223.HKD","BK1096","LU1251922891.USD","LU0188438112.USD","SG9999001846.SGD","LU1282651121.HKD","LU1960683339.HKD","LU0132412106.USD","LU2237443549.SGD","LU0228367735.SGD","LU0314109678.HKD","LU0823038988.USD","LU0572944931.SGD","LU0072913022.USD","LU0231483743.USD","LU1211504680.USD","SG9999018857.SGD","LU2097828805.USD","LU2251237306.USD","LU2106854487.HKD","600196","IE00BZ08YR35.GBP","LU0164865239.USD","LU0449515922.USD","LU0463099449.HKD","LU1814569148.SGD","LU0737861772.HKD","LU0261947096.USD","LU0173614495.USD","LU0642271901.SGD","BK1618","LU0251144936.SGD","LU1951186391.HKD","BK1531","LU0269904917.USD","IE0003895053.USD","LU2039709279.SGD","LU2097828557.USD","LU1568876251.USD","LU0683595622.HKD","IE00BZ08YS42.EUR","LU0651946864.USD","LU0080751232.USD","LU0326948709.USD","IE00B031HW06.USD","LU0384037296.USD","LU0359201612.USD","LU0049853897.USD","HK0000352291.HKD","LU0898667661.SGD","LU1439102457.SGD","LU1196710864.SGD","LU0143863198.USD","LU0784639295.USD","LU2237443895.HKD","LU2362541273.HKD","LU1794554557.SGD","LU2279701549.SGD","LU0345775950.USD","LU0651947912.USD","BK1114","LU0828237940.HKD","LU2449936058.SGD","LU0211977185.USD","IE0031814852.USD","LU0149534421.HKD","BK1521","SG9999015952.SGD","LU0890818403.SGD","LU1804176565.USD","LU2247934214.USD","LU0049112450.USD","LU0254981946.USD","06936","BK1589","IE0008368742.USD","LU2265009873.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780784","title":"Fosun Pharma's Unit's Registration Application for Blood Stasis Syndrome Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780784","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780784?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:14","pubTimestamp":1778674455,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  unit Hebei Wanbang Folon Pharmaceutical's drug registration application for Tao Hong Si Wu Tang Granules was accepted by China's National Medical Products Administration.The drug is intended to be used for blood deficiency and blood stasis syndrome, according to a Wednesday Hong Kong bourse filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK0028","BK0175","BK0239","BK1593","BK0188","BK1191","BK0187","BK0060","BK0196","BK1515","BK0096","02196","BK0183","600196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":-0.0032},{"period":"1month","weight":-0.1292},{"period":"3month","weight":-0.1414},{"period":"6month","weight":-0.2182},{"period":"1year","weight":-0.1384},{"period":"ytd","weight":-0.1653}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0549},{"period":"3month","weight":-0.0329},{"period":"6month","weight":0.0267},{"period":"1year","weight":0.1797},{"period":"ytd","weight":0.0061}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。根据工信部中国医药工业信息中心颁布的“2024年度中国医药工业百强企业榜单”，本集团位列第5位。此外，在ESG方面，复星医药于报告期内荣登2025《财富》ESG影响力榜单，成为唯一入选该榜单的中国医药企业。根据MSCI于2025年7月公布的ESG年度评级结果，本集团MSCIESG评级提升至AA级。在AI领域，复星医药凭借自主研发的PharmAID医药智能平台荣获福布斯“2025中国人工智能科技创新场景应用企业TOP10”。","serverTime":1781111323226,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction